About the Aquadex SmartFlow® System The Aquadex SmartFlow System provides a clinically proven treatment, a simple, flexible and intelligent approach to removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for transience (up to 8 hours) or prolonged use (more than 8 hours in patients requiring hospitalization) in adult and pediatric patients weighing 20 kg or more whose fluid overload does not respond to medical treatment, adding diuretics. All remedies shall be administered through a physical care provider, in an outpatient or inpatient clinical setting, under medical prescription, either of whom has obtained education in extracorporeal therapies.
About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is a medical generation company committed to transforming the lives of fluid-overloaded patients through science, collaboration, and innovation. The company aims to commercialize the Aquadex SmartFlow® formula for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis and has a wholly-owned subsidiary in Ireland. For more information, www. nuwellis. com or us on LinkedIn or X.
Forward-Looking StatementsCertain statements contained in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding new market opportunities and expected expansion in 2024 and beyond. there. Forward-looking statements are predictions, projections and other statements about long-term events that are based on existing expectations and assumptions and are therefore subject to risks and uncertainties. Many points may also cause actual long-term events to differ materially from the forward-looking statements contained in this release, including, but not limited to, risks related to our ability to implement our go-to-market strategy, the effect of the pandemic COVID-19. -19 pandemic, the option that we may not be able to raise sufficient mandatory budget for our planned operations, our post-marketing clinical knowledge gathering activities, the benefits of our products to patients, our expectations in product progression and the marketing efforts, for our ability to build a market and physician acceptance. our products, our potentially competitive product offerings, intellectual property coverage, our ability to integrate acquired businesses, our expectations regarding the expected synergies and benefits of the acquired businesses and other dangers and uncertainties described in our SEC filings. Forward-looking statements speak only as of the date on which they are made. Nuwellis undertakes no legal responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, long-term developments or otherwise.
CONTACTS